Best Peptides for Fat Loss: 10 Ranked

Best Peptides for Fat Loss: 10 Ranked (2026)

Fat loss peptides have moved far beyond the single-mechanism era. In 2026, researchers have access to GLP-1 receptor agonists, dual and triple agonists, growth hormone secretagogues, NNMT inhibitors, and monoamine reuptake inhibitors — each attacking body fat through different pathways.

The problem is choosing. Some peptides deliver 20%+ weight loss in clinical trials but come with significant gastrointestinal side effects. Others target visceral fat specifically or enhance metabolism at the cellular level without appetite suppression. The right choice depends on your mechanism preference, evidence tolerance, and specific fat loss goals.

This article ranks 10 fat loss peptides by clinical evidence, mechanism of action, and practical considerations. Each section summarizes the key data and links to the full peptide page for dosing, vendor comparisons, and deep-dive research.

Quick Comparison Table

1. Tirzepatide — Dual GIP/GLP-1 Agonist

Tirzepatide is the current frontrunner for total weight loss in completed phase 3 trials. As a dual GIP and GLP-1 receptor agonist, it activates two incretin pathways simultaneously — suppressing appetite through GLP-1 while GIP signaling enhances insulin sensitivity and may improve fat metabolism.

The SURMOUNT-1 trial enrolled 2,539 adults with obesity and demonstrated mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 22.5% (15 mg) at 72 weeks. More than half of participants on the highest dose achieved 20%+ body weight loss — a threshold previously considered unreachable with pharmacotherapy alone [1]. Body composition analysis from the same trial confirmed the weight loss is predominantly from adipose tissue rather than lean mass — dual-energy X-ray absorptiometry (DXA) showed approximately two-thirds of total weight lost was fat mass, with relative preservation of lean body mass. This ratio is clinically meaningful because many aggressive caloric deficits sacrifice muscle, which worsens metabolic rate long-term.

The SURMOUNT-2 trial extended these findings to adults with both obesity and type 2 diabetes, a population that historically responds less well to weight loss pharmacotherapy. Even in this more metabolically resistant group, tirzepatide produced 12.8% (10 mg) and 14.7% (15 mg) weight loss at 72 weeks, alongside significant HbA1c reductions. The fact that efficacy held in a diabetic population — where insulin resistance typically blunts weight loss — underscores the potency of dual incretin activation.

Gastrointestinal side effects (nausea, diarrhea, constipation) are the primary tolerability concern, affecting roughly 50-60% of participants, though most events are mild to moderate and transient. Most GI symptoms peak during dose escalation and diminish over subsequent weeks, which is why slow titration schedules are standard. For full dosing protocols, see the tirzepatide page.

2. Retatrutide — Triple Agonist (GIP/GLP-1/Glucagon)

Retatrutide adds glucagon receptor activation to the dual agonist framework, creating a three-pronged attack on body fat. Glucagon increases energy expenditure and hepatic fat oxidation — mechanisms absent from GLP-1-only or dual-agonist approaches.

In the phase 2 obesity trial, retatrutide at 12 mg produced 24.2% mean weight loss at 48 weeks, with the weight loss curve still trending downward at study end [2]. This is the highest weight loss percentage reported in any obesity trial to date, though it remains phase 2 data with smaller sample sizes than SURMOUNT or STEP.

The triple agonist mechanism comes with a broader side effect profile. Phase 3 trials are underway and will determine whether these results hold at scale. For current evidence and dosing, visit the retatrutide page.

3. Semaglutide — GLP-1 Receptor Agonist

Semaglutide is the most extensively studied fat loss peptide, with the largest body of phase 3 evidence and the longest follow-up data. It works through selective GLP-1 receptor activation, reducing appetite, slowing gastric emptying, and improving central satiety signaling.

The STEP 1 trial demonstrated 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo in 1,961 adults with obesity [3]. The STEP 5 extension confirmed sustained efficacy at two years, with 15.2% weight loss maintained at 104 weeks. This durability data is a significant advantage — most fat loss interventions show diminishing returns over time, while semaglutide held steady.

The STEP 8 trial provided the first head-to-head comparison of semaglutide 2.4 mg against liraglutide 3.0 mg over 68 weeks. Semaglutide produced 15.8% weight loss versus 6.4% for liraglutide, with a higher proportion of participants reaching clinically meaningful thresholds at every level (5%, 10%, 15%, and 20% weight loss). This trial effectively established semaglutide as the superior GLP-1 mono-agonist for weight management, though liraglutide retains a role where daily dosing flexibility is preferred.

Semaglutide is also available in oral formulation, making it the only injectable GLP-1 agonist with a non-injection option. However, the oral version has important limitations: bioavailability is significantly lower than the subcutaneous form, the tablet must be taken on an empty stomach with minimal water, and the highest approved oral dose delivers less GLP-1 exposure than the 2.4 mg injectable. Higher-dose oral formulations are in development but are not yet widely available. For most fat loss applications, the weekly injectable remains the standard.

Gastrointestinal side effects remain the primary concern, occurring in approximately 44% of participants. For dosing protocols and vendor pricing, see the semaglutide page.

4. Cagrilintide + Semaglutide (CagriSema)

Cagrilintide is a long-acting amylin analog that, when combined with semaglutide, targets two distinct appetite pathways. Amylin promotes satiety through the area postrema in the brainstem, while GLP-1 works through hypothalamic and vagal circuits — complementary mechanisms that produce additive weight loss.

The REDEFINE 1 phase 3 trial showed 20.4% mean weight loss at 68 weeks with the cagrilintide-semaglutide combination versus 3.0% with placebo [4]. This establishes cagrilintide as a meaningful augmentation strategy rather than a standalone agent.

Gastrointestinal adverse events were more frequent with the combination (79.6%) than placebo (39.9%), but most were mild to moderate. For the full cagrilintide evidence review, see the cagrilintide page.

5. Survodutide — Dual Glucagon/GLP-1 Agonist

Survodutide takes a different dual-agonist approach than tirzepatide by combining glucagon and GLP-1 receptor activation instead of GIP and GLP-1. The glucagon component directly increases hepatic lipid oxidation and energy expenditure, making survodutide particularly relevant for individuals with hepatic steatosis (fatty liver) alongside obesity.

The phase 2 trial in 387 adults with obesity showed dose-dependent weight loss: 6.2% (0.6 mg), 12.5% (2.4 mg), 13.2% (3.6 mg), and 14.9% (4.8 mg) at 46 weeks versus 2.8% with placebo [5]. Phase 3 SYNCHRONIZE trials are underway. The liver-specific benefits may differentiate survodutide from other incretin-based approaches for metabolically unhealthy obesity.

For current data and updates, visit the survodutide page.

6. Liraglutide — First-Generation GLP-1 Agonist

Liraglutide was the first GLP-1 receptor agonist approved for chronic weight management and remains relevant as a well-characterized, lower-intensity option. It requires daily injections (versus weekly for semaglutide and tirzepatide), which is a practical disadvantage but allows for more granular dose titration.

The SCALE Obesity and Prediabetes trial randomized 3,731 adults without diabetes and found 8.0% mean weight loss at 56 weeks with liraglutide 3.0 mg versus 2.6% with placebo [6]. While the absolute weight loss is lower than newer agents, liraglutide has the most mature long-term safety dataset in the GLP-1 class.

For dosing and vendor comparisons, see the liraglutide page.

7. Tesofensine — Triple Monoamine Reuptake Inhibitor

Tesofensine works through an entirely different mechanism than incretin-based peptides. As a triple reuptake inhibitor of serotonin, dopamine, and norepinephrine, it suppresses appetite through central monoaminergic pathways while simultaneously increasing resting energy expenditure. This positions it as a non-hormonal alternative for fat loss.

A phase 2 trial in 203 obese patients showed dose-dependent weight loss of 4.5% (0.25 mg), 9.2% (0.5 mg), and 10.6% (1.0 mg) over 24 weeks versus 2.0% with placebo [7]. The 0.5 mg dose produced roughly twice the weight loss of the approved dose of sibutramine (a similar mechanism drug) with a comparable side effect profile. Phase 3 trials have been conducted in select markets, though tesofensine is not FDA-approved.

Cardiovascular monitoring is recommended due to modest increases in heart rate and blood pressure observed at higher doses. See the tesofensine page for protocols and sourcing.

8. Tesamorelin — GHRH Analog for Visceral Fat

Tesamorelin is the only FDA-approved therapy specifically indicated for visceral fat reduction (in the context of HIV-associated lipodystrophy). As a growth hormone-releasing hormone analog, it stimulates pulsatile GH release, which preferentially mobilizes visceral adipose tissue without the supraphysiologic GH levels seen with direct GH administration.

Clinical trials showed tesamorelin reduced visceral adipose tissue by approximately 15-18% over 6-12 months, with concurrent improvements in liver enzymes and inflammatory markers [8]. Unlike GLP-1 agonists, tesamorelin does not primarily work through appetite suppression — it targets the metabolic activity of visceral fat directly. This makes it a complementary option for individuals whose primary concern is central adiposity rather than total body weight.

Tesamorelin does not produce dramatic scale weight changes, so it is best assessed via waist circumference or imaging. Full protocols on the tesamorelin page.

9. 5-Amino-1MQ — NNMT Inhibitor

5-Amino-1MQ represents a fundamentally different approach to fat loss. By inhibiting nicotinamide N-methyltransferase (NNMT), it preserves cellular NAD+ and SAM pools that are depleted in obesity, restoring metabolic function at the enzymatic level rather than suppressing appetite or stimulating hormone receptors.

Animal studies show NNMT inhibition reverses high-fat-diet-induced obesity, improves insulin sensitivity, and reduces fat mass without affecting food intake. The oral bioavailability is a practical advantage, though the absence of human clinical trial data is the primary limitation.

5-Amino-1MQ is the strongest option for individuals interested in metabolic enhancement without appetite suppression. For dosing and evidence review, see the 5-amino-1MQ page.

10. AOD-9604 — Growth Hormone Fragment

AOD-9604 is a modified fragment (amino acids 177-191) of human growth hormone that retains the lipolytic activity of GH without its growth-promoting or diabetogenic effects. It stimulates fat breakdown and inhibits lipogenesis through a mechanism independent of the GH receptor.

Preclinical studies demonstrated increased fat oxidation and weight loss in obese mice, and early human trials showed a favorable safety profile. However, AOD-9604's clinical development stalled after phase 2, and no pivotal efficacy trials were completed. The evidence base is significantly weaker than every other peptide on this list. It remains popular in compounding and research peptide markets, but expectations should be calibrated to the limited data.

For current sourcing and protocols, see the AOD-9604 page.

Stacking Recommendations

The most evidence-backed fat loss stack is cagrilintide plus semaglutide, validated in phase 3 trials with 20.4% weight loss [4]. Beyond that combination, practical stacking strategies target different mechanisms:

• GLP-1 agonist + tesamorelin: Appetite suppression plus targeted visceral fat mobilization. Complementary mechanisms with non-overlapping side effects.
• GLP-1 agonist + 5-amino-1MQ: Incretin-based appetite control plus NAD+-driven metabolic enhancement. Oral 5-amino-1MQ adds no injection burden.
• Tesofensine + tesamorelin: Non-incretin stack for individuals who cannot tolerate GLP-1 gastrointestinal effects. Monoaminergic appetite suppression plus GH-mediated visceral fat reduction.

Avoid stacking multiple GLP-1 agonists (semaglutide + liraglutide) as they compete for the same receptor with no additive benefit and compounded side effects.

How to Choose: Decision Framework

The choice between fat loss peptides comes down to three factors: mechanism preference, evidence requirements, and specific fat loss goals.

If maximum total weight loss is the priority: Tirzepatide (phase 3 proven) or retatrutide (highest reported loss, phase 2) lead the field. Both require injections and carry meaningful GI side effect profiles.

If long-term safety data matters most: Semaglutide and liraglutide have the deepest safety databases, with multi-year follow-up across thousands of participants. Liraglutide is the most conservative choice; semaglutide offers better efficacy with weekly dosing.

If visceral fat is the specific target: Tesamorelin is the only FDA-approved option for visceral adipose reduction and works through GH-mediated pathways rather than appetite suppression.

If you want to avoid appetite suppression entirely: 5-Amino-1MQ (NNMT inhibition) and tesamorelin (GHRH stimulation) work through metabolic enhancement rather than reducing food intake. Both have more limited evidence bases.

If oral dosing is required: 5-Amino-1MQ and tesofensine are oral compounds. Oral semaglutide is also available but at lower doses than the injectable formulation used in obesity trials.

Injection Frequency and Practical Burden

Injection frequency varies significantly across these peptides and affects long-term adherence. Semaglutide and tirzepatide are dosed once weekly, which most users find manageable. Liraglutide requires daily injections, which increases compliance burden but allows finer dose adjustments — useful when titrating around side effects. Tesamorelin is also a daily injection. For the orally available compounds (5-amino-1MQ, tesofensine, oral semaglutide), the injection question is eliminated entirely, though oral semaglutide has strict fasting requirements that carry their own compliance challenges.

Side Effect Tolerance

GI side effects are the dominant tolerability issue across GLP-1-based peptides. The incidence follows a roughly dose-dependent pattern: tirzepatide at 15 mg and cagrilintide-semaglutide combinations produce GI events in 60-80% of participants, while semaglutide 2.4 mg sits around 44% and liraglutide 3.0 mg around 40%. For individuals with a history of gastroparesis, severe acid reflux, or prior GI surgery, the non-incretin options (tesamorelin, 5-amino-1MQ, tesofensine) may be more appropriate. Tesofensine carries its own tolerability considerations — modest heart rate and blood pressure increases require cardiovascular baseline assessment and ongoing monitoring.

Cost Considerations

Cost structures differ substantially by compound class. Prescription GLP-1 agonists (semaglutide, tirzepatide, liraglutide) are the most expensive category, particularly through retail pharmacy channels. Compounding pharmacy pricing offers lower cost points but introduces quality variability. Research peptides like 5-amino-1MQ and AOD-9604 are generally less expensive per month but lack regulatory quality controls. When comparing costs, factor in expected treatment duration — GLP-1 agonists typically require ongoing use to maintain weight loss, while the optimal treatment length for newer compounds is not yet established.

What the Evidence Actually Shows

The gap between the strongest and weakest evidence on this list is enormous. Tirzepatide and semaglutide have tens of thousands of participants across multiple phase 3 trials. AOD-9604 and 5-amino-1MQ have zero completed human efficacy trials for obesity. Every decision should weight the strength of evidence alongside the reported efficacy numbers.

Phase 2 results (retatrutide, survodutide, tesofensine) are promising but historically shrink by 2-5 percentage points when replicated in larger phase 3 populations. This attrition is consistent across obesity pharmacotherapy: smaller phase 2 populations with tighter enrollment criteria produce better outcomes than the broader groups enrolled in pivotal trials. The retatrutide phase 2 result of 24.2% is particularly likely to moderate because the 48-week weight loss curve had not yet plateaued — the final steady-state number could land anywhere in a wide range.

Placebo response rates also deserve attention. In most obesity trials, placebo groups lose 2-4% of body weight from the behavioral components of study participation (dietary counseling, regular weigh-ins, clinical monitoring). This means the true drug-attributable effect is the treatment group minus placebo — so semaglutide's 14.9% in STEP 1 represents roughly 12.5% of drug-specific weight loss after subtracting the 2.4% placebo response. Headlines almost never make this distinction.

Finally, understand the difference between intention-to-treat (ITT) and completer analyses. ITT includes all randomized participants with conservative imputation for dropouts; completer analyses include only those who finished. Completer results run 2-4 percentage points higher than ITT numbers. Most headline figures use the ITT treatment-policy estimand — the more conservative and clinically relevant number. When evaluating any peptide, confirm which analysis you are reading.

Monitoring and Bloodwork

Any fat loss peptide protocol should include baseline and periodic bloodwork to track both efficacy and safety markers. The specific panel depends on the peptide class, but several markers are universally relevant.

Metabolic panel and fasting glucose: Rapid weight loss can shift insulin sensitivity, electrolyte balance, and kidney function. A comprehensive metabolic panel at baseline, 3 months, and 6 months catches early signals. Fasting glucose and fasting insulin track improvements in insulin resistance — one of the primary metabolic benefits of effective fat loss.

HbA1c: For anyone using GLP-1-based peptides (semaglutide, tirzepatide, liraglutide, survodutide, retatrutide), HbA1c provides a 3-month average of glycemic control. Even in non-diabetic individuals, tracking HbA1c documents metabolic improvement beyond scale weight.

Lipid panel: Total cholesterol, LDL, HDL, and triglycerides typically improve with meaningful fat loss, but the pattern varies by peptide. GLP-1 agonists tend to shift all lipid markers favorably. Tesamorelin has shown mixed lipid effects in some populations. Baseline and every 3-6 months is standard.

Liver enzymes (ALT, AST, GGT): Particularly important with survodutide and retatrutide, which include glucagon receptor activation that directly affects hepatic metabolism. Transient early elevations can reflect beneficial hepatic fat clearance, but sustained ALT above 3x the upper limit of normal warrants protocol reassessment.

Thyroid function (TSH, free T4): GLP-1 receptor agonists carry a boxed warning regarding medullary thyroid carcinoma in rodent studies, though human causation has not been established. Baseline thyroid testing is prudent before any GLP-1-based peptide, with periodic monitoring every 6-12 months.

Related Reading

• Semaglutide Dosing Guide
• Tirzepatide Results: Week-by-Week Timeline
• 5-Amino-1MQ Benefits: 6 NNMT Effects Proven
• AOD-9604 Dosing Guide
• Retatrutide Dosing Guide
• Tesamorelin Dosing Guide
• Tesofensine Dosing Guide

References

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
2. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
4. Novo Nordisk. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025. PMID: 40544433
5. le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. PMID: 38330987
6. Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. PMID: 26132939
7. Astrup A, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906-1913. PMID: 18950853
8. Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial. JAIDS. 2010;53(3):311-322. PMID: 20101189